OneVentures appoints Investment Analyst

Australian Venture Capital firm OneVentures has announced the appointment of Sakura Holloway as an investment analyst, effective May 2017.

In this role, Holloway will provide specialist skills in IP due diligence and management.

Holloway joins OneVentures following two years as chief IP counsel at dual-listed Australian biotech company Benitec Biopharma Ltd, where she managed the company's IP portfolio and supported the company's US IPO and NASDAQ listing.

Previously she held scientific roles with UTS and the Garvan Institute, and IP/commercial roles with Cephalon, CSIRO and FB Rice.

She is joined at OneVentures by investment manager and fellow new-appointee, Sarah Meibusch.

In a statement, the firm said that the appointments of Meibusch & Holloway will provide "additional capacity to source, structure and manage healthcare sector opportunities" for its recently launched $170m OneVentures Healthcare Fund III.

Managing partner and head of OneVentures' healthcare practice, Dr Paul Kelly, added: "OneVentures' hands-on approach to deal structuring and management requires access to an expert and experienced professional team. Sakura and Sarah bring new skills that perfectly complement those of the existing healthcare team members. We are delighted to welcome them to OneVentures."